NEUP

Neuphoria Therapeutics Inc

3.05

Oct 30 • 3:59 PM ET -0.01 (-0.33%)

3.05

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: VTGN TNXP NMRA SILO RLMD ANRO MNOV ENVB CING ADXN

| Held by: PSIL VTI VXF

Scroll to Statements

Index	-
Market Cap	16.50M
Enterprise Value	-3.34M
Income	-13.45M
Sales	1.17M
Book/sh	4.55
Cash/sh	3.67
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	1
IPO	Dec 16, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	14.10
P/B	0.67
P/C	0.83
P/FCF	-
EV/EBITDA	-
EV/Sales	-2.85
Quick Ratio	27.85
Current Ratio	27.85
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-6.19
EPS next Y	-2.46
EPS next Q	-
EPS this Y	40.29%
EPS next Y	-1.23%
EPS next 5Y	-
EPS past 3/5Y	-196.42% -98.30%
Sales past 3/5Y	- -
EPS Y/Y TTM	79.08%
Sales Y/Y TTM	-
EPS Q/Q	-113.83%
Sales Q/Q	-92.17%
Earnings	Sep 02
EPS/Sales Surpr.	0.00% -

Insider Own	5.02%
Insider Trans	0.00%
Inst Own	41.51%
Inst Trans	5.57%
ROA	-
ROE	-
ROIC	-54.68%
Gross Margin	43.54%
Oper. Margin	-835.53%
Profit Margin	-1145.66%
SMA20	-8.86%
SMA50	-14.69%
SMA200	-26.73%
Trades

Shs Outstand	5.41M
Shs Float	5.14M
Short Float	0.13%
Short Ratio	0.20
Short Interest	0.01M
52W High	5.53 -44.85%
52W Low	3.03 0.59%
Volatility	4.18% 3.62%
ATR (14)	0.13
RSI (14)	25.47
Beta	0.75
Rel Volume	2.20
Avg Volume	31.99K
Volume	70,253

Perf Week	-11.34%
Perf Month	-13.11%
Perf Quarter	-22.39%
Perf Half Y	-41.57%
Perf YTD	-21.39%
Perf Year	-30.68%
Perf 3Y	-89.99%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	7.00
Prev Close	3.06
Price	3.05
Change %	-0.33%

Consensus

Strong Buy

Avg. Price Target

$7.00

Implied Upside

+129.5%

Analysts5incl. previous ratings

Rating Distribution5 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 28, 2023	Upgrade	HH.C. Wainwright	Neutral → Buy	$8	+162.3%
Sep 28, 2023	Reiterated	MMaxim Group	Buy	$7 → $10	+227.9%
Jan 10, 2022	Initiated	HH.C. Wainwright	Buy	$54	+1,670.5%
Jan 10, 2022	Initiated	EEvercore ISI	Outperform	$17	+457.4%
Jan 10, 2022	Initiated	CCantor Fitzgerald	Overweight	$52	+1,604.9%
Jan 10, 2022	Initiated	BBerenberg	Buy	$21	+588.5%

Oct-09-26 02:45AM	Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial (Proactive)
Aug-04-26 04:40PM	Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jul-29-26 10:36PM	Are CBZ, SAFT, NEUP Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jul-27-26 07:41AM	Scancell sees high demand in retail share offer, seals £15.7m from UK investors (Proactive) +5.77%
Jul-24-26 09:00AM	SMALL-CAP MOVERS: Nasdaq-bound Scancell catches the eye as AIM's headcount falls to 612 (Proactive) -7.14%
03:35AM	Loading…
Jul-23-26 03:35AM	Scancell to join Nasdaq through Neuphoria merger and $89 million funding package (Proactive) +17.72%
Jul-01-26 06:01PM	MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimers Drug Trial Under Neuphoria Partnership (Stocktwits) -18.76%
Jun-26-26 04:15PM	Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc (GlobeNewswire) +5.06%
09:45AM	Scancell confirms advanced talks over reverse merger with Neuphoria (Proactive)
Dec-08-25 08:00AM	Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees (GlobeNewswire) +6.32%
Dec-04-25 08:00AM	Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium (GlobeNewswire)
Dec-01-25 08:00AM	Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions (GlobeNewswire)
Nov-24-25 08:00AM	Neuphoria Therapeutics Inc. Sends Letter to Stockholders (GlobeNewswire)
Nov-11-25 07:00AM	Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value (GlobeNewswire)
Oct-27-25 04:29PM	Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process (GlobeNewswire) -27.40%
12:53PM	Loading…
Oct-22-25 12:53PM	Neuphoria scraps social anxiety hopeful after Phase III miss (Clinical Trials Arena) -11.34%
Oct-20-25 04:15PM	Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder (GlobeNewswire) -68.51%
Sep-29-25 04:54PM	Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates (GlobeNewswire)
Sep-04-25 07:00AM	Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD) (GlobeNewswire) -8.31%
Aug-28-25 04:05PM	Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +19.47% -7.21%
May-27-25 04:10PM	Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting (GlobeNewswire)
May-20-25 04:22PM	Neuphoria Provides First Quarter 2025 Business Updates (GlobeNewswire) +9.86%
Apr-15-25 08:00AM	Neuphoria Provides a Review of 2024 and Highlights 2025 Plans (GlobeNewswire)
Mar-03-25 07:30AM	Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025 (GlobeNewswire) -5.19%
Feb-12-25 07:00AM	Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck (GlobeNewswire)
Jan-25-25 05:13PM	Why Neuphoria Therapeutics Inc. (NEUP) Surged on Friday (Insider Monkey)
Dec-24-24 05:49PM	Bionomics Strategic Shift with Neuphoria Redomiciliation (TipRanks) +118.29% -32.88%
Dec-16-24 04:05PM	Bionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-Domiciliation (GlobeNewswire) -11.76%
Dec-12-24 04:05PM	Results of Scheme Meeting (GlobeNewswire) +5.29% +6.88%
Dec-09-24 08:00AM	Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence (GlobeNewswire)
04:05PM	Loading…
Dec-03-24 04:05PM	Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting (GlobeNewswire) -6.56%
Dec-02-24 05:01PM	Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States (GlobeNewswire)
Nov-08-24 04:15PM	Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement (GlobeNewswire) +6.53% -9.12%
Nov-07-24 08:00AM	Bionomics to Present at the 2024 CNS Summit (GlobeNewswire) +36.25%
Nov-04-24 04:15PM	Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program (GlobeNewswire) +157.79%
Oct-23-24 06:00AM	Bionomics to Present at the ThinkEquity Conference (GlobeNewswire)
Oct-14-24 08:00AM	Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC (GlobeNewswire) -6.82%
Oct-08-24 08:50AM	Bionomics CEO believes company has significant, unrealized value (TipRanks)
Oct-07-24 08:00AM	Bionomics Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision (GlobeNewswire)
Oct-01-24 06:30AM	Bionomics Limited announces intention to re-domicile to the United States (GlobeNewswire) -11.20%
Sep-03-24 06:30AM	Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Jul-31-24 06:30AM	Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder (GlobeNewswire) -9.78%
Jul-29-24 04:30PM	Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024 (GlobeNewswire) +24.01%
Jul-18-24 06:30AM	Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder (GlobeNewswire)
May-31-24 08:00AM	Bionomics Limited Announces Private Placement of up to $70.0 Million (GlobeNewswire) -14.97%
May-20-24 06:30AM	Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting (GlobeNewswire)
Mar-21-24 06:00AM	Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (GlobeNewswire)
Feb-22-24 04:30PM	Bionomics to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire) -8.00%
Feb-05-24 03:11AM	10 Best Australian Stocks To Buy (Insider Monkey)
Feb-04-24 11:01AM	7 Strong Buy Stocks Under $20: February 2024 (InvestorPlace)
Jan-22-24 06:00AM	Bionomics Provides a Review of 2023 and of 2024 Plans (GlobeNewswire)
Jan-05-24 06:00AM	Bionomics to Present at Biotech Showcase 2024 (GlobeNewswire)
Dec-06-23 08:00AM	Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting (GlobeNewswire) +5.08%
Oct-30-23 02:02PM	12 Best Stocks For Day Trading (Insider Monkey)
Oct-16-23 08:00AM	Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder (GlobeNewswire) +14.18%
Sep-29-23 08:51AM	Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244% (Zacks) -19.88%
12:13AM	Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) (PR Newswire)
Sep-28-23 08:03AM	Why Is Bionomics (BNOX) Stock Up 347% Today? (InvestorPlace) +242.13%
07:09AM	Bionomics' midphase PTSD trial hits primary endpoint, briefly tripling its battered share price (FierceBiotech.com)
06:00AM	Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) (GlobeNewswire)
Sep-14-23 06:00AM	Bionomics Announces Update on the 7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD (GlobeNewswire) -25.14%
Aug-24-23 11:50AM	Bionomics (BNOX) Up on Positive Updates on PTSD & SAD Candidate (Zacks) +7.91%
Aug-23-23 06:00AM	Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210 (GlobeNewswire) +15.83%
Jul-31-23 06:00AM	Quarterly Activities and Cashflow Report (GlobeNewswire) -14.14%
Jul-25-23 06:00AM	Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX) (GlobeNewswire) -15.93%
Jul-15-23 08:27PM	Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jul-03-23 06:00AM	Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth (GlobeNewswire) +5.95%
Jun-15-23 08:00AM	Bionomics to Present at Upcoming June Investor Conferences (GlobeNewswire)
May-30-23 06:00AM	Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (GlobeNewswire) -5.62%
Apr-28-23 06:00AM	Quarterly Activities and Cashflow Report (GlobeNewswire)
Apr-27-23 06:00AM	Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) (GlobeNewswire)
Mar-09-23 10:54AM	Bionomics Reveals Detailed Data From Its Flunked Anxiety Trial, Shows Reductions In Anxiety Across Multiple Phases (Benzinga) -26.24%
Mar-08-23 07:00PM	Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD) (GlobeNewswire) +7.39%
Mar-03-23 09:55AM	Bears are Losing Control Over Bionomics Limited Unsponsored ADR (BNOX), Here's Why It's a 'Buy' Now (Zacks)
Feb-24-23 03:05PM	Bionomics First Half 2023 Earnings: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022) (Simply Wall St.) +19.03%
Feb-23-23 06:00AM	Bionomics Half-Year Report (GlobeNewswire) +9.47%
Feb-05-23 07:02PM	Will Bionomics (ASX:BNO) Spend Its Cash Wisely? (Simply Wall St.)
Jan-30-23 06:23PM	Quarterly Activities and Cashflow Report (GlobeNewswire) -6.20%
Dec-19-22 03:29PM	All Focus Shifts To Bionomics' PTSD Study After Anxiety Trial Disappoints (Benzinga) -13.38%
09:30AM	Bionomics' Social Anxiety Disorder Study Fails To Meet Primary Endpoint (Benzinga)
Dec-18-22 07:34PM	Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder (GlobeNewswire)
Dec-15-22 06:35PM	Bionomics appoints Spyridon Spyros Papapetropoulos as President and Chief Executive Officer (GlobeNewswire)
Dec-02-22 06:00AM	Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting (GlobeNewswire)
Nov-21-22 06:13PM	Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United States (GlobeNewswire)
Nov-16-22 06:36PM	Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States (GlobeNewswire) -17.41%
Nov-02-22 06:00AM	Bionomics Limited to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-25-22 06:00AM	Quarterly Activities Report for September 2022 (GlobeNewswire)
Oct-18-22 06:00AM	Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million (GlobeNewswire)
Oct-07-22 04:39PM	Bionomics (ASX:BNO) adds AU$20m to market cap in the past 7 days, though investors from five years ago are still down 84% (Simply Wall St.)
Oct-04-22 06:00AM	Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference (GlobeNewswire)
Sep-21-22 06:00AM	Bionomics to Host KOL Webinar on BNC210 and Social Anxiety Disorder (GlobeNewswire)
Sep-15-22 09:55AM	Can Bionomics Limited Unsponsored ADR (BNOX) Climb 329% to Reach the Level Wall Street Analysts Expect? (Zacks)
Aug-31-22 06:00AM	Bionomics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-30-22 09:55AM	Does Bionomics Limited Unsponsored ADR (BNOX) Have the Potential to Rally 329% as Wall Street Analysts Expect? (Zacks)
Aug-27-22 06:26PM	We're Keeping An Eye On Bionomics' (ASX:BNO) Cash Burn Rate (Simply Wall St.)
Aug-25-22 06:00AM	Bionomics reports Full Year Financial Results (GlobeNewswire) +7.42%
Aug-08-22 06:00AM	Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M (GlobeNewswire)
Jul-29-22 06:00AM	Quarterly Activities Report for June 2022 (GlobeNewswire)
Jul-08-22 06:00AM	Bionomics to Participate in William Blairs Biotech Focus Conference 2022 (GlobeNewswire) +8.82%
Jun-27-22 06:00AM	Bionomics Limited to Participate in the H.C. Wainwright Mental Health Conference (GlobeNewswire)

Show Previous News

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded in 1996 and is headquartered in Millis, MA.

Ph.D.Dr. Spyridon Papapetropoulos M.D.

M.B.A.Mr. Timothy M. Cunningham CPA

Senior Vice President of Business OperationsDr. Julie Kerner Ph.D.

F.C.A.Mr. Adrian Hinton BEC

C.A.Mr. Rajeev Chandra B.Com.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NEUP

Neuphoria Therapeutics Inc

Upgrade your Finviz experience